natgillin/translations-raw huggingface dataset:
In the second main study, the change in pain intensity after ten minutes was between 2.0 and 2.7 points after receiving doses of Instanyl compared with 1.3 after receiving placebo.
U drugom glavnom ispitivanju, promjena u intenzitetu boli nakon deset minuta bila je između 2,0 i 2,7 nakon primljene doze lijeka Instanyl u usporedbi s 1,3 nakon doze placeba.
In the second part of the study including patients with prior anticancer therapy but without risk factors for cardiac toxicity, sunitinib was generally tolerable and clinically manageable at the dose of 15 mg/m2/day on schedule 4/2.
U drugom dijelu ispitivanja, uključujući bolesnike na prethodnoj terapiji protiv raka, ali bez faktora rizika za kardiotoksičnost, sunitinib je općenito bio podnošljiv i klinički se mogao primjenjivati u dozi od 15 mg/m2/dan po shemi 4/2.
In the second part, the risk of experiencing a disease flare was reduced by 64% with Ilaris, compared with placebo.
U drugom dijelu ispitivanja, rizik od rasplamsavanja bolesti smanjen je za 64 % s lijekom Ilaris, u usporedbi s placebom.
In the second pivotal study (study 2), the primary endpoint was SPID30, which was also statistically significant compared to placebo (p<0.0001).
U drugom pivotalnom kliničkom ispitivanju (ispitivanje 2) primarni ishod bila je vrijednost SPID30 koja je također bila statistički značajna u usporedbi s placebom (p<0,0001).
In the second prevention study, blood clots or blood-clot related death occurred in 0.4% (3 out of 681) of patients treated with Pradaxa, compared with 5.6% (37 out of 662) of patients treated with placebo.
U drugom ispitivanju koje je istražilo sprječavanje, krvni ugrušci ili smrtni slučajevi povezani s krvnim ugrušcima zabilježeni su u 0,4 % (3 od 681) bolesnika koji su liječeni lijekom Pradaxa, u usporedbi s 5,6 % (37 od 662) bolesnika koji su liječeni varfarinom.
In the second study in 48 patients with mild to moderate asthma who had previously been shown to have bronchoconstrictive reactions to adenosine monophosphate, the rate of FEV1 reduction > 15% from baseline was the same (4%) following both Rapiscan and placebo dosing.
U drugom ispitivanju na 48 bolesnika s blagom do umjerenom astmom koji su ranije reagirali bronhokonstrikcijom na adenozinmonofosfat, stopa smanjenja FEV1 > 15% od početnih vrijednosti bila je jednaka (4%) nakon primjene doze i Rapiscana i placeba.
In the second study in women weighing above 60 kg, the average number of eggs collected from each woman was 13.8 in those treated with Elonva compared with 12.6 in those treated with follitropin beta.
U drugom ispitivanju provedenom u žena s tjelesnom težinom većom od 60 kg, prosječan broj jajašca prikupljen od svake žene iznosio je 13,8 u žena liječenih lijekom Elonva u usporedbi s 12,6 u žena liječenih folitropinom beta.
In the second study involving 63 children less than 12 years of age, children treated with NovoEight had an average of 5.33 bleedings per year.
U drugom ispitivanju koje je obuhvatilo 63 djece mlađe od 12 godina, djeca liječena lijekom NovoEight imala su prosječno 5,33 krvarenja godišnje.
In the second study of 34 subjects with different impaired hepatic function compared to normal subjects, there was a 1.6-fold, 3.3-fold and 3.6-fold increase in exposure (i.e.
U drugom ispitivanju provedenom u 34 ispitanika s različitim stupnjevima oštećenja funkcije jetre u usporedbi s normalnim ispitanicima, došlo je do povećanja od 1,6, 3,3 odnosno 3,6 puta u izloženosti (tj.
In the second study survival of Eravac vaccinated rabbits was 93% compared with 50% for rabbits given placebo.
U drugom je ispitivanju stopa preživljavanja među kunićima koji su primili cjepivo Eravac bila 93 % u usporedbi sa stopom od 50 % u kunića koji su primili placebo.
In the second study, 15% (10 out of 65) of patients receiving Signifor 40 mg and 20% (13 out of 65) of patients receiving Signifor 60 mg responded to treatment, compared with none of the 68 patients given octreotide or lanreotide.
U drugom ispitivanju, 15% (10 od 65) bolesnika koji su primali lijek Signifor u dozi od 40 mg i 20% (13 od 65) bolesnika koji su primali lijek Signifor u dozi od 60 mg odgovorilo je na liječenje, u usporedbi s niti jednim od 68 bolesnika koji su primali oktreotid ili lanreotid.
In the second study, 30% of the patients adding Rapamune failed treatment (68 out of 277), compared with 48% of those adding placebo (62 out of 130).
U drugom ispitivanju 30 % bolesnika koji su uzimali lijek Rapamune kao dodatnu terapiju nije odgovorilo na liječenje (68 od 277), u usporedbi s 48 % u grupi koja je uzimala placebo (62 od 130).
In the second study, 38 out of 69 patients (55%) taking 10 mg Revlimd did not need a blood transfusion for at least 182 days, compared with 4 out of 67 (6%) taking placebo.
U drugom ispitivanju, 38 od 69 bolesnika (55 %) koji su uzimali 10 mg Revlimida nije trebalo transfuziju krvi najmanje 182 dana u usporedbi s 4 od 67 (6 %) bolesnika koji su uzimali placebo.
In the second study, 46 (81%) of the 57 patients had a platelet count above 50 million platelets per millilitre at least once during the study.
U drugom ispitivanju, 46 od 57 bolesnika (81 %) imalo je broj trombocita iznad 50 milijuna trombocita po milimetru barem jednom tijekom ispitivanja.
In the second study, 52% of the patients receiving Relistor opened their bowels at least twice within four hours of the first four doses (32 out of 62), compared with 8% of those receiving placebo (6 out of 71).
U drugom ispitivanju, kod 52 % bolesnika koji su primali lijek Relistor došlo je do otvaranja crijeva najmanje dva puta u roku od četiri sata od uzimanja prve četiri doze (32 od 62), u usporedbi s 8 % onih koji su primali placebo (6 od 71).
In the second study, 53% (8 out of 15) of children who received Revestive responded to treatment, while none responded to the standard treatment (0 out of 5).
Tijekom drugog ispitivanja 53% djece (njih 8 od 15) koja su primala lijek Revestive ostvarilo je pozitivan rezultat liječenja, dok ni jedno dijete nije ostvarilo pozitivan rezultat na standardno liječenje (0 od 5).
In the second study, 62% of women using Senshio reported relief from vaginal dryness after 12 weeks (compared with 53% in the placebo group).
U drugom ispitivanju, 62% žena koje su koristile Senshio prijavilo je blaže simptome vaginalne suhoće nakon 12 tjedana (u usporedbi s 53% u grupi koja je primala placebo).
In the second study, 81% of patients receiving Zinforo were cured (235 out of 289) compared with 76% of the patients receiving ceftriaxone (206 out of 273).
U drugom ispitivanju izliječeno je 81 % bolesnika koji su dobivali lijek Zinforo (235 od 289), u usporedbi sa 76 % bolesnika koji su dobivali lijek ceftriakson (206 od 273).
In the second study, 85% of patients receiving Zinforo were cured (291 out of 342) compared with 86% of the patients receiving the combination of vancomycin and aztreonam (289 out of 338).
U drugom ispitivanju izliječeno je 85 % bolesnika koji su dobivali lijek Zinforo (291 od 342), u usporedbi s 86 % bolesnika koji su dobivali kombinaciju lijekova vankomicin i aztreonam (289 od 338).
In the second study, after 14 weeks, 35% of patients who received Simponi alone (54 out of 153) achieved 20% reductions compared with 18% of patients who received placebo (28 out of 155).
U drugom ispitivanju reumatoidnog artritisa, nakon 14 tjedana 35 % bolesnika koji su primali lijek Simponi (54 od 153) postiglo je smanjenje od 20 % u usporedbi s 18 % u bolesnika koji su primali placebo (28 od 155).
In the second study, among the 28 adults and adolescents with cancer that had not responded to two or more previous treatments, five (18%) had a complete response to treatment.
U drugom ispitivanju, od 28 odraslih osoba i adolescenata s rakom koji nisu odgovorili na dva ili više prethodnih ispitivanja, pet (18%) je imalo potpuni odgovor na terapiju.
In the second study, around 59% of previously untreated patients with wild-type RAS who were given Vectibix plus FOLFIRI responded to treatment.
U drugom ispitivanju, oko 59 % prethodno neliječenih bolesnika s divljim tipom gena RAS koji su primili Vectibix u kombinaciji s „FOLFIRI ” kemoterapijskim protokolom odgovorili su na liječenje.
In the second study, Edurant was compared with efavirenz, when both medicines were given in combination with a fixed regimen of antiviral medicines consisting of tenofovir disoproxil and emtricitabine or two other nucleoside or nucleotide reverse transcriptase inhibitors.
U drugom ispitivanju Edurant je uspoređen s efavirenzom, pri čemu su oba lijeka uzimana u kombinaciji s fiksnim režimom protuvirusnih lijekova koji se sastoji od tenofovirdizoproksila i emtricitabina ili dva druga nukleozidna ili nukleotidna inhibitora reverzne transkriptaze.
In the second study, Eliquis was compared with placebo (a dummy treatment) and its effectiveness was measured by looking at the number of patients who either had problems related to clotting in the veins or who died of any cause during treatment.
U drugom ispitivanju, Eliquis je uspoređen s placebom (lažnim liječenjem), a njegova djelotvornost izmjerena je na temelju broja bolesnika koji su imali problem povezan s nastankom ugrušaka u venama ili koji su preminuli tijekom terapije.
In the second study, in 58% of patients Benlysta 10 mg/kg was effective compared with 44% of patients who were given placebo.
U drugom ispitivanju, doza lijeka Benlysta od 10 mg/kg bila je djelotvorna u 58 % bolesnika, u usporedbi s 44 % bolesnika koji su dobivali placebo.
In the second study, involving 269 patients who had not been treated before, Imbruvica was more effective than the cancer medicine chlorambucil at delaying progression of the cancer.
U drugom ispitivanju koje je obuhvatilo 269 bolesnika koji prethodno nisu liječeni, lijek Imbruvica se pokazao djelotvornijim u usporavanju napredovanja raka od lijeka protiv raka naziva klorambucil.
In the second study, it took 26.4 months for the disease to get worse in patients taking Revlimid plus dexamethasone, compared with 22.7 months for those on standard treatment.
U drugom ispitivanju, bila su potrebna 26,4 mjeseca kako bi se bolest pogoršala u bolesnika koji su uzimali Revlimid s deksametazonom u usporedbi s 22,7 mjeseci za one koji su uzimali standardnu terapiju.
In the second study, it was the number of patients who had a platelet count between 50,000 and 400,000 per microlitre during six months of treatment.
U drugom ispitivanju to je bio broj bolesnika kod kojih je broj trombocita iznosio između 50 000 i 400 000/µl tijekom šest mjeseci terapije.
In the second study, Kiovig was shown to be effective in increasing the platelet count.
U drugom je ispitivanju utvrđeno da je lijek Kiovig djelotvoran u povećavanju broja trombocita.
In the second study, LAVENTAIR 55/22 micrograms showed improvements compared with placebo in change from baseline in lung volume measures at trough and at 3 hours post dose at Week 12 (inspiratory capacity: 198 ml and 238 ml respectively, residual volume: -295 ml and -351 ml respectively and functional residual capacity: -238 ml and -302 ml respectively); all p<0.001).
U drugom je ispitivanju LAVENTAIR od 55/22 mikrograma u 12. tjednu doveo do poboljšanja u usporedbi s placebom s obzirom na promjenu plućnog volumena izmjerenog na kraju intervala doziranja i 3 sata nakon primjene doze u odnosu na početnu vrijednost (udisajni kapacitet: 198 ml odnosno 238 ml, rezidualni volumen: -295 ml do -351 ml i funkcionalni rezidualni kapacitet: -238 ml do -302 ml; p<0,001* za sve).
In the second study, on day 1 the percentage or patients who had reduction of facial redness 3 hours after application was 19.6% (29 out of 148 patients) for Mirvaso compared with 0 % (none out of 145 patients) for placebo.
U drugom ispitivanju, 1. dan postotak ili broj bolesnika u kojih je zabilježeno smanjenje crvenila lica nakon 3 sata od primjene iznosio je 19,6% (29 od 148 bolesnika) za lijek Mirvaso u odnosu na 0 % (niti jedan od 145 bolesnika) za placebo.
In the second study, patients given Yervoy with dacarbazine survived an average of 11 months, compared with 9 months in those given placebo plus dacarbazine, but about a third of the patients given Yervoy were unable to complete treatment due to side effects.
U drugom ispitivanju, bolesnici koji su primili Yervoy s dakarbazinom preživjeli su prosječno 11 mjeseci u usporedbi s 9 mjeseci u bolesnika koji su primili placebo i dakarbazin, no otprilike trećina bolesnika koja je primila Yervoy nije mogla završiti liječenje zbog nuspojava.
In the second study, patients receiving Lucentis on its own or as an add-on to laser photocoagulation could see after one year an average of 5 letters more than patients receiving laser photocoagulation on its own.
U drugom ispitivanju, bolesnici koji su primali sam Lucentis ili Lucentis kao dodatak laserskoj fotokoagulaciji nakon godine dana mogli su vidjeti prosječno 5 slova više od bolesnika koji su primali samu lasersku fotokoagulaciju.
In the second study, progression-free survival was 9.4 months in the patients receiving Avastin and 8.0 months in those receiving placebo.
U drugom ispitivanju, preživljenje bez progresije iznosilo je 9,4 mjeseca u slučaju bolesnika koji su primali Avastin i 8,0 mjeseci u onih koji su primali placebo.
In the second study, seizures were at least halved in 39% (61 out of 158 patients) of the patients on 600 mg Trobalt a day and in 47% (70 out of 149 patients) of the patients on 900 mg a day, compared with 19% (31 out of 164) of the patients on placebo.
U drugom ispitivanju, napadaji su barem prepolovljeni u 39% bolesnika (u 61 bolesnika od 158 bolesnika), koji su uzimali 600 mg Trobalta na dan, i u 47% bolesnika (kod 70 bolesnika od 149 bolesnika), koji su uzimali 900 mg Trobalta na dan, u usporedbi s 19% bolesnika (31 bolesnik od 164), koji su uzimali placebo.
In the second study, the average reduction was 1.6 points after 24 weeks of treatment with Bydureon, compared with an average reduction of 0.9 points with exenatide given twice daily.
U drugom je ispitivanju prosječno smanjenje iznosilo 1,6 bodova nakon liječenja lijekom Bydureon u trajanju od 24 tjedna, u usporedbi s prosječnim smanjenjem od 0,9 bodova nakon liječenja eksenatidom koji je primjenjivan dvaput na dan.
In the second study, the brain tumour shrank by at least half in 35% of patients (27 out of 78 patients) treated with Votubia, compared with none of the 39 patients who received placebo.
U drugom ispitivanju, tumor mozga smanjio se za najmanje pola u 35 % bolesnika (27 od 78 bolesnika) liječenih lijekom Votubia, što nije zabilježeno niti kod jednog od 39 bolesnika koji su primili placebo.
In the second study, the fall in symptom score was 20.0 in the Invega group and 10.8 in the placebo group.
U drugom ispitivanju, pad u rezultatu simptoma bio je 20,0 u grupi koja je primala lijek Invega i 10,8 u grupi koja je primala placebo.
In the second study, the figures were around 22% for Ozurdex after 90 days and 12% for the sham treatment.
U drugom ispitivanju brojke su iznosile oko 22 % za Ozurdex nakon 90 dana i 12 % za lažno liječenje.
In the second study, the overall response rate at the time of analysis was 37% (52 of 140 patients) and the average length of response was 9.2 months, and similar results were seen when the study was completed.
U drugom ispitivanju ukupna stopa odgovora u trenutku analize iznosila je 37 % (52 od 140 bolesnika), s prosječnom duljinom odgovora od9,2 mjeseca, a slični su rezultati zabilježeni i nakon dovršetka ispitivanja.
In the second study, the treatment difference in EET between LAVENTAIR 55/22 micrograms and placebo was 21.9 seconds (p=0.234) at Week 12.
U drugom je ispitivanju terapijska razlika EET vrijednosti između lijeka LAVENTAIR od 55/22 mikrograma i placeba iznosila 21,9 sekundi (p=0,234) nakon 12 tjedana.
In the second study, the women whose cancer was expressing large quantities of HER2 taking Tyverb in combination with letrozole survived for an average of 35.4 weeks without their disease getting worse.
U drugom ispitivanju, žene čiji je karcinom pokazivao ekspresiju velikih količina HER2, a uzimale su Tyverb u kombinaciji s letrozolom, preživjele su prosječno 35,4 tjedna a da se njihova bolest nije pogoršala.
In the second study, three-month treatment with Esmya was as effective as leuprorelin in reducing heavy uterine bleeding, as 90.3% of women treated with Esmya had reduced bleeding compared with 89.1% of women treated with leuprorelin.
U drugom ispitivanju, djelotvornost lijeka Esmya bila je jednaka djelotvornosti leuprorelina u smanjivanju obilnog krvarenja iz maternice budući da je u 90,3 % žena liječenih lijekom Esmya zabilježeno smanjeno krvarenje u usporedbi s 89,1 % žena liječenih leuprorelinom.
In the second study, treatment with Abasaglar or Lantus was compared in 759 patients with type 2 diabetes, as an addition to diabetes medicines taken by mouth.
U drugom ispitivanju terapija lijekom Abasaglar ili Lantus uspoređena je u 759 bolesnika s dijabetesom tipa 2 kao dodatak peroralnim antidijabeticima.
In the second trial, children aged from 2 to 15 years with moderate to severe atopic dermatitis received twice daily treatment for three weeks of 0.03% tacrolimus ointment, 0.1% tacrolimus ointment or 1% hydrocortisone acetate ointment.
U drugom ispitivanju, djeca od 2 do 15 godina starosti s umjerenim do teškim atopijskim dermatitisom liječena su dvaput na dan tijekom tri tjedna mašću s 0,03% takrolimusa, mašću s 0,1% takrolimusa ili mašću s 1% hidrokortizon acetata.
In the second week, a patient’s assigned dose could be increased to 0.30 mg/kg if the patient had 2 or fewer rescue-free laxations up to day 8.
Tijekom drugog tjedna doza koju su bolesnici primali mogla se povisiti na 0,30 mg/kg ako je bolesnik imao 2 ili manje laksacija bez primjene dodatnog laksativa do 8. dana.
In the second year after the introduction of Prevenar 13 the total number of CAP cases due to the 6 additional vaccine serotypes in Prevenar 13 was reduced from 27 to 7 isolates (74%).
U drugoj godini nakon uvođenja Prevenara 13 ukupni broj izvanbolničkih slučajeva upala pluća zbog 6 dodanih serotipova u cjepivu u Prevenaru 13 smanjeno je od 27 do 7 izolata (74%) .
In the second year of life, Nimenrix can also be given at the same time as combined diphtheria - tetanus - acellular pertussis vaccines, including combination diphtheria - tetanus - acellular pertussis vaccines with hepatitis B, inactivated polio or Haemophilus influenzae type b, such as DTaP-HBV- IPV/Hib vaccine and 13-valent pneumococcal conjugate vaccine.
U drugoj godini života, Nimenrix se također može dati istovremeno s kombiniranim cjepivom protiv difterije, tetanusa i nestaničnog pertusisa, uključujući kombinaciju cjepiva protiv difterije, tetanusa i nestaničnog pertusisa i cjepiva protiv hepatitisa B, dječje paralize (inaktivirano) ili Haemophilus influenzae tipa b, kao što je DTaP-HBV-IPV/Hib cjepivo i 13-valentnim konjugiranim pneumokoknim cjepivom.
In the second year of the studies, patients continued to receive the initially randomised dosage but on a modified dosing schedule guided by assessment of visual and anatomic outcomes with a protocol- defined maximum dosing interval of 12 weeks.
U drugoj godini ispitivanja bolesnici su nastavili primati dozu koja im je bila nasumično dodijeljena na početku, ali prema prilagođenom rasporedu doziranja određenom prema vizualnim i anatomskim ishodima uz maksimalni interval doziranja od 12 tjedana definiran planom ispitivanja.
In the Segment II reproductive studies in rats and rabbits, defibrotide has shown maternal toxicity by inducing a high rate of haemorrhagic abortion when infused intravenously over two hours at all dose levels tested including doses close to the human dose.
U ispitivanjima reprodukcije Segment II u štakora i kunića, defibrotid je pokazao maternalnu toksičnost uzrokujući visoku stopu hemoragijskih pobačaja kada je davan intravenskom infuzijom tijekom dva sata pri svim testiranim dozama, uključujući one blizu ljudske doze.
In the setting of central nervous system (CNS) inflammation in MS, it is the interaction of α4β1 with VCAM-1, CS-1 and osteopontin that mediates the firm adhesion and transmigration of leukocytes into the brain parenchyma and may perpetuate the inflammatory cascade in CNS tissue.
Za pojavu upale središnjeg živčanog sustava u multiploj sklerozi odgovorna je interakcija α4β1 s VCAM-1, CS-1 i osteopontinom koja dovodi do snažne adhezije i prodora leukocita u parenhim mozga te može pokrenuti upalni proces u tkivu središnjeg živčanog sustava.
In the setting of hyponatraemia, the treatment duration is determined by the underlying disease and its treatment.
U slučaju hiponatremije, trajanje liječenja je određeno postojećom bolesti i terapijom iste.
In the short-term clinical studies of brivaracetam in epilepsy patients, there were no cases of completed suicide and suicide attempt, however both have been reported in open-label extension studies (see section 4.4).
U kratkoročnim kliničkim ispitivanjima brivaracetama provedenima u bolesnika s epilepsijom, nisu zabilježeni slučajevi izvršenih samoubojstava ni pokušaja samoubojstva, ali je oboje prijavljeno u otvorenim nastavcima ispitivanja (vidjeti dio 4.4).
In the short-term, placebo-controlled, fixed-dose adolescent study, a higher percentage of INVEGA-treated subjects (6-19% depending on dose) had an increase in body weight of ≥7% compared to placebo-treated subjects (2%).
U kratkotrajnom, placebom-kontroliranom ispitivanju fiksne doze u adolescenata, viši postotak ispitanika liječenih lijekom INVEGA (6-19% ovisno o dozi) imalo je povećanu tjelesnu težinu od ≥7% u uspredbi s ispitanicima koji su primali placebo (2%).
In the shorter (10 week) placebo controlled induction trial, GEMINI III, the types of adverse reactions reported were similar but occurred at lower frequency than the longer 52 week trials.
U kraćem (10-tjednom) placebom kontroliranom uvodnom ispitivanju, GEMINI III, vrste prijavljenih nuspojava bile su slične, ali su se javljale s nižom učestalosti nego u duljim 52-tjednim ispitivanjima.
In the SINGLE study a mean change from baseline of 12.6 mol/L was observed after 96 weeks of treatment.
U ispitivanju SINGLE je nakon 96 tjedana liječenja primijećena srednja promjena od 12,6 µmol/l u odnosu na početnu vrijednost.
In the single-arm, open label trial in SAA, three (7%) patients were diagnosed with MDS following treatment with eltrombopag, in the two ongoing studies (ELT116826 and ELT116643), 1/28 (4%) and 1/62 (2%) subject has been diagnosed with MDS or AML in each study.
U otvorenom ispitivanju teške aplastične anemije s jednom skupinom, u troje (7%) bolesnika dijagnosticiran je MDS nakon liječenja eltrombopagom, u dva ispitivanja koja su u tijeku (ELT116826 i ELT116643), u 1/28 (4%) i 1/62 (2%) ispitanika dijagnosticiran je MDS ili AML u svakom od ispitivanja.
In the single-arm, open-label trial in SAA, patients had bone marrow aspirates evaluated for cytogenetic abnormalities.
U otvorenom ispitivanju teške aplastične anemije s jednom skupinom, u bolesnika su se ocjenjivale citogenetske abnormalnosti u aspiratima koštane srži.
In the SIRTURO group, all of the five deaths due to tuberculosis occurred in patients whose sputum culture status at last visit was ‘not converted’.
U skupini liječenoj lijekom SIRTURO, svih pet smrti zbog tuberkuloze dogodile su se u bolesnika čiji je status kulture sputuma na zadnjoj viziti bio ‘bez konverzije’.
In the small subgroup of patients with deletion 17p, only a positive trend was observed compared to Clb (HR=0.42, p=0.0892); no benefit was observed compared to RClb.
U malenoj podskupini bolesnika koji su imali deleciju 17p primijećen je samo pozitivan trend u odnosu na Clb (HR=0,42, p=0,0892); nije primijećena dobit u usporedbi s RClb.
In the solvent: benzyl alcohol and benzalkonium chloride as preservatives and water for injections.
U otapalu: konzervansi benzilni alkohol i benzalkonijev klorid i voda za injekcije.
In the solvent: carmellose sodium, mannitol, poloxamer 188, water for injections.
U otapalu: karmelozanatrij, manitol, poloksamer 188, voda za injekcije.